Prosecution Insights
Prosecution Insights
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Institute Of Organic Chemistry And Biochemistry Ascr V V I has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending action represents the entirety of the company's current prosecution efforts in this field. Such a focused portfolio allows for a dedicated strategy to address the specific requirements of the Biotechnology & Pharmaceuticals domain.
The examination of the portfolio is handled by a distinct examiner, HIBSHMAN, SARAH GRACE. Because there is only a single distinct art unit involved, the prosecution process is contained within a single administrative group. This simplicity eliminates the need to manage different examiner preferences or art unit trends, as the entire focus is on the interaction with the examiner.
HIBSHMAN, SARAH GRACE is the busiest examiner for the company, currently overseeing a pending office action. The alignment of the examiner and the art unit provides a clear path for the company's prosecution strategy. This structure means that the company's patent goals are tied to a single point of contact within the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIAMOND, ALAN D | 1 | 71.5% | +8.5% |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19288215 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | DIAMOND, ALAN D | 3991 | §112 | Non-Final OA | — | Pending | Aug 01, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial